

# MAKScientific

DISCOVERING MEDICATIONS FOR METABOLIC DISORDERS,  
PAIN, ADDICTION, AND NEUROLOGICAL DISEASES

## A NEW APPROACH FOR TREATING LIVER DISEASE AND METABOLIC DISORDERS

MAKScientific LLC ([www.makscientific.com](http://www.makscientific.com)) is a Boston-based and privately held pharmaceutical company strategically positioned to develop and commercialize new therapeutic compounds for the treatment of chronic liver disease and metabolic syndrome. Based on pivotal work originating at the University of Connecticut (USA), the Company is engaged in the development of novel and orally available small molecule CB1 receptor antagonists for the treatment of these disorders.

One lead compound (AM6545) is a peripherally-restricted neutral antagonist of the CB1 receptor that exhibits excellent receptor selectivity and favorable preliminary pre-clinical efficacy and safety characteristics. Our AM6545 project is currently at the late pre-clinical stage with kg amounts of GMP-quality material available for use. Several backup compounds at different stages of pre-clinical development are also available.

MAKScientific is seeking a partner to support advanced AM6545 preclinical profiling, IND filing and follow-on clinical trials.

## CB1 RECEPTOR PROJECT AT A GLANCE

### Therapeutic Target

- Cannabinoid Receptor 1 (CB1), a validated drug target for metabolic syndrome.
- Antagonism or inverse agonism of the CB1 receptor shown to produce therapeutically relevant effects of metabolic syndrome and liver disease in animal models and humans.

### Compounds

- Synthetic, orally available, highly selective, small molecule, nanomolar and peripherally-restricted antagonists of CB1 receptor.
- Neutral antagonists bind CB1 without influencing normal constitutive receptor function.
- Potent and peripherally-restricted activity in animal models of liver disease and obesity.
- Preliminary biological and PK/ADME data favorable and comparable to Rimonobant (Accomplia®) without Rimonobant's side effects
- A short development runway of 12 months to IND approval.

### Intellectual Property

- Broad patent portfolio covering composition of matter and methods of use in largest markets.

## MANAGEMENT

**Robert L. Buchanan,**  
CEO  
+1-617-418-1600  
[r.buchanan@makscientific.com](mailto:r.buchanan@makscientific.com)

**Alexandros Makriyannis,**  
Director and Co-founder  
+1-617-373-4200  
[a.makriyannis@neu.edu](mailto:a.makriyannis@neu.edu)